Desmoid Tumors

Disease

Related News

Immunome Submits NDA for Varegacestat in Desmoid Tumors After Positive Phase 3 RINGSIDE Trial

Apr 29, 2026

Immunome submitted an NDA to the FDA for varegacestat in desmoid tumors after the Phase 3 RINGSIDE trial showed an 84% reduction in progression risk (HR=0.16) and a 56% objective response rate. The company plans to file in Q2 2026.

Iterion Therapeutics Doses First Patient in Colorectal Cancer Trial for Wnt Inhibitor Tegavivint

Mar 25, 2026

Iterion Therapeutics has dosed the first patient in a phase 1/2 trial of its Wnt/β-catenin inhibitor tegavivint for metastatic colorectal cancer. The expansion builds on promising monotherapy activity observed in advanced hepatocellular carcinoma, targeting a pathway activated in over 90% of colorectal cancer patients.